Cargando…

Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?

Significant research has been conducted to better understand the extensive, heterogeneous molecular features of triple-negative breast cancer (TNBC). We reviewed published TNBC molecular classifications to identify major groupings that have potential for clinical trial development. With the ultimate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Le Du, Fanny, Eckhardt, Bedrich L., Lim, Bora, Litton, Jennifer K., Moulder, Stacy, Meric-Bernstam, Funda, Gonzalez-Angulo, Ana M., Ueno, Naoto T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4536987/ https://www.ncbi.nlm.nih.gov/pubmed/25973541

Ejemplares similares

Challenges and perspective of drug repurposing strategies in early phase clinical trials
por: Kato, Shumei, et al.
Publicado: (2015)

Identification of triple-negative breast cancer cell lines classified under the same molecular subtype using different molecular characterization techniques: Implications for translational research
por: Espinosa Fernandez, Jose Rodrigo, et al.
Publicado: (2020)

Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer
por: Arango, Natalia Paez, et al.
Publicado: (2017)

Early-stage Triple-negative Breast Cancer: Time to Optimize Personalized Strategies
por: Abuhadra, Nour, et al.
Publicado: (2022)

A target of potential RELAvance in inflammatory breast cancer
por: Eckhardt, Bedrich L., et al.
Publicado: (2017)

Clinically relevant inflammatory breast cancer patient-derived xenograft–derived ex vivo model for evaluation of tumor-specific therapies
por: Eckhardt, Bedrich L., et al.
Publicado: (2018)

Personalized cancer therapy—leveraging a knowledge base for clinical decision-making
por: Dumbrava, Ecaterina Ileana, et al.
Publicado: (2018)

Eicosapentaenoic acid in combination with EPHA2 inhibition shows efficacy in preclinical models of triple-negative breast cancer by disrupting cellular cholesterol efflux
por: Torres-Adorno, Angie M., et al.
Publicado: (2018)

Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy
por: Caudle, Abigail S, et al.
Publicado: (2012)

TAK228 enhances antitumor activity of eribulin in triple negative breast cancer
por: Owusu-Brackett, Nicci, et al.
Publicado: (2019)

Rates of immune cell infiltration in patients with triple-negative breast cancer by molecular subtype
por: Harano, Kenichi, et al.
Publicado: (2018)

Reverse phase protein array identification of triple-negative breast cancer subtypes and comparison with mRNA molecular subtypes
por: Masuda, Hiroko, et al.
Publicado: (2017)

Punctuated Copy Number Evolution and Clonal Stasis in Triple-Negative Breast Cancer
por: Gao, Ruli, et al.
Publicado: (2016)

Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors
por: Wheler, Jennifer J., et al.
Publicado: (2016)

Targeting EGFR in Triple Negative Breast Cancer
por: Ueno, Naoto T., et al.
Publicado: (2011)

PTEN in triple-negative breast carcinoma: protein expression and genomic alteration in pretreatment and posttreatment specimens
por: Chen, Hui, et al.
Publicado: (2023)

Comparison of molecular profile in triple-negative inflammatory and non-inflammatory breast cancer not of mesenchymal stem-like subtype
por: Funakoshi, Yohei, et al.
Publicado: (2019)

Whole Genome Sequencing in Cancer Clinics
por: Chen, Ken, et al.
Publicado: (2014)

Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast Cancer
por: Abuhadra, Nour, et al.
Publicado: (2022)

Oxidative Phosphorylation Is a Metabolic Vulnerability in Chemotherapy-Resistant Triple-Negative Breast Cancer
por: Evans, Kurt W., et al.
Publicado: (2021)

Impact of TP53 mutations in Triple Negative Breast Cancer
por: Mitri, Zahi I., et al.
Publicado: (2022)

Adapting a Natural Language Processing Tool to Facilitate Clinical Trial Curation for Personalized Cancer Therapy
por: Zeng, Jia, et al.
Publicado: (2014)

Rare subtypes of triple negative breast cancer: Current understanding and future directions
por: Thomas, Alexandra, et al.
Publicado: (2023)

Application of Artificial Intelligence to Plasma Metabolomics Profiles to Predict Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
por: Irajizad, Ehsan, et al.
Publicado: (2022)

Predictive Roles of Baseline Stromal Tumor-Infiltrating Lymphocytes and Ki-67 in Pathologic Complete Response in an Early-Stage Triple-Negative Breast Cancer Prospective Trial
por: Abuhadra, Nour, et al.
Publicado: (2023)

Novel therapeutic strategies in the treatment of triple-negative breast cancer
por: Oualla, Karima, et al.
Publicado: (2017)

Clinical outcomes based on multigene profiling in metastatic breast cancer patients
por: Basho, Reva K., et al.
Publicado: (2016)

ONC201 and an MEK Inhibitor Trametinib Synergistically Inhibit the Growth of Triple-Negative Breast Cancer Cells
por: Lim, Bora, et al.
Publicado: (2021)

cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer
por: Sohn, Joohyuk, et al.
Publicado: (2014)

Targeting translation initiation in breast cancer
por: Akcakanat, Argun, et al.
Publicado: (2014)

Comparison of molecular subtype distribution in triple-negative inflammatory and non-inflammatory breast cancers
por: Masuda, Hiroko, et al.
Publicado: (2013)

Somatic mutations, clinicopathologic characteristics, and survival in patients with untreated breast cancer with bone-only and non-bone sites of first metastasis
por: Kono, Miho, et al.
Publicado: (2018)

Future of Triple Negative Breast Cancer: Can Immunotherapy Treat This Deadly Subtype of Breast Cancer?
por: Salimi, Mona
Publicado: (2018)

Changes in Triple-Negative Breast Cancer Molecular Subtypes in Patients Without Pathologic Complete Response After Neoadjuvant Systemic Chemotherapy
por: Masuda, Hiroko, et al.
Publicado: (2022)

The rapamycin-regulated gene expression signature determines prognosis for breast cancer
por: Akcakanat, Argun, et al.
Publicado: (2009)

Comprehensive analysis of long non-coding RNAs in human breast cancer clinical subtypes
por: Su, Xiaoping, et al.
Publicado: (2014)

Implications of constructed biologic subtype and its relationship to locoregional recurrence following mastectomy
por: Dominici, Laura S, et al.
Publicado: (2012)

TNBCtype: A Subtyping Tool for Triple-Negative Breast Cancer
por: Chen, Xi, et al.
Publicado: (2012)

Subtyping Of Triple Negative Breast Carcinoma On The Basis Of RTK Expression
por: Hessel, Harald, et al.
Publicado: (2018)

Triple-negative breast cancer molecular subtyping and treatment progress
por: Yin, Li, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_on4lsh24uvra5ti88383sfeqhc